Trial
NCT03445533
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Idera Pharmaceuticals, Inc.
Collaborators
Bristol-Myers Squibb
Condition
Metastatic Melanoma
Intervention
Ipilimumab
Why stopped
Lack of Efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-11-08